It is Poised to be a Bull Market for Evaxion Biotech A/S (EVAX)

Evaxion Biotech A/S (NASDAQ: EVAX) stock jumped 22.63% on Friday to $2.33 against a previous-day closing price of $1.90. With 46.12 million shares changed hands, the volume of the stock remained heavier than its average volume of 31490.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.5199 whereas the lowest price it dropped to was $2.1500. The 52-week range on EVAX shows that it touched its highest point at $25.04 and its lowest point at $1.51 during that stretch. It currently has a 1-year price target of $15.50.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of EVAX was up-trending over the past week, with a rise of 13.66%, but this was down by -13.70% over a month. Three-month performance surged to 32.39% while six-month performance fell -28.31%. The stock lost -71.27% in the past year, while it has lost -47.29% so far this year. A look at the trailing 12-month EPS for EVAX yields -1.15 with Next year EPS estimates of -1.18. For the next quarter, that number is -0.27. This implies an EPS growth rate of -59.00% for this year and -13.50% for next year.

Float and Shares Shorts:

At present, 23.84 million EVAX shares are outstanding with a float of 3.59 million shares on hand for trading. On Jul 14, 2022, short shares totaled 0.18 million, which was 0.77% higher than short shares on Jun 14, 2022. In addition to Dr. Lars Aage-Staal Wegner M.D. as the firm’s Chief Exec. Officer, Dr. Niels Iversen Moeller M.D. serves as its Co-Founder, VP of Bus. & Director.

Institutional Ownership:

Through their ownership of 2.88% of EVAX’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 0.97% of EVAX, in contrast to 0.01% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in EVAX with 0.53% of the stake, Telemetry Investments LLC holds 122,000 shares worth 122,000. A second-largest stockholder of EVAX, Citadel Advisors LLC, holds 83,586 shares, controlling over 0.36% of the firm’s shares. Renaissance Technologies LLC is the third largest shareholder in EVAX, holding 11,600 shares or 0.05% stake. With a 0.01% stake in EVAX, the Fidelity Nasdaq Composite Index F is the largest stakeholder. A total of 2,428 shares are owned by the mutual fund manager.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for EVAX since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With EVAX analysts setting a high price target of $18.00 and a low target of $16.00, the average target price over the next 12 months is $17.33. Based on these targets, EVAX could surge 672.53% to reach the target high and rise by 586.7% to reach the target low. Reaching the average price target will result in a growth of 643.78% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. EVAX will report FY 2022 earnings on 04/04/2023. Analysts have provided yearly estimates in a range of -$0.97 being high and -$1.14 being low. For EVAX, this leads to a yearly average estimate of -$1.04. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Evaxion Biotech A/S surprised analysts by $0.10 when it reported -$0.20 EPS against a consensus estimate of -$0.30. The surprise factor in the prior quarter was $0.08. Based on analyst estimates, the high estimate for the next quarter is -$0.22 and the low estimate is -$0.34. The average estimate for the next quarter is thus -$0.27.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]